Get the Stockscreener App
11.44
0.87%
-0.10
After Hours:
9.00
-2.44
-21.33%
Scisparc Ltd stock is traded at $11.44, with a volume of 181.05K.
It is down -0.87% in the last 24 hours and up +65.56% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$11.54
Open:
$10.16
24h Volume:
181.05K
Relative Volume:
0.17
Market Cap:
$6.56M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0494
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
+16.62%
1M Performance:
+65.56%
6M Performance:
-26.95%
1Y Performance:
+299.73%
1-Day Range:
$10.16
$11.98
1-Week Range:
$8.40
$15.79
52-Week Range:
$2.61
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
11.44 | 6.62M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scisparc Ltd Stock (SPRC) Latest News
NeuroThera completes acquisition of 54% stake in CliniQuantum - Investing.com UK
SciSparc more than doubles as NeuroThera wins conditional nod for CliniQuantum deal - MSN
In today's session, these stocks are experiencing unusual volume. - ChartMill
Which stocks are gapping on Thursday? - ChartMill
SPRC Stock Pops As SciSparc Pushes Into Quantum Clinical Analytics - timothysykes.com
SciSparc Subsidiary NeuroThera Labs Closes Majority Acquisition of CliniQuantum - TipRanks
These stocks that are showing activity before the opening bell on Thursday. - ChartMill
NeuroThera completes acquisition of 54% stake in CliniQuantum By Investing.com - Investing.com India
SciSparc (NASDAQ: SPRC) unit NeuroThera acquires 54% of CliniQuantum in CAD$9.46M share deal - Stock Titan
Quantum trial-analysis startup CliniQuantum sold in C$9.5M SciSparc deal - Stock Titan
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Completes Acquisition of 54% Stake in CliniQuantum Ltd. - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum - GlobeNewswire
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd. - marketscreener.com
SciSparc's Quantum Gambit: Betting on AI to Remake Drug Trials - BriefGlance
Director Itschak Shrem Sells Shares of SciSparc Ltd (SPRC) - GuruFocus
SciSparc (SPRC) director Itschak Shrem sells 462 Ordinary Shares at $10 - Stock Titan
SciSparc Shares Jumped Last Week, Market Awaits Monday Deal Deadline - Bez Kabli
SciSparc Subsidiary Wins Conditional TSXV Nod for CliniQuantum Acquisition, Amends Deal Terms - TipRanks
SciSparc (Nasdaq: SPRC) unit to buy 54% of CliniQuantum in share deal - Stock Titan
SciSparc stock surges 200% on NeuroThera acquisition progress - Investing.com
SPRC News | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest - RTTNews
SciSparc Ltd. (SPRC) Stock: Shares Soar 202% on NeuroThera’s TSX Approval - MEXC
SciSparc stock surges 157% after subsidiary gets conditional TSX approval for major acquisition - Pluang
Why is SciSparc stock skyrocketing on Thursday? - MSN
SciSparc Ltd. (SPRC) Stock Explodes 202% Following NeuroThera’s TSX Exchange Milestone - MEXC
SciSparc Jumps 150.8% as Subsidiary Wins Conditional Exchange Approval for CliniQuantum Deal - Moomoo
SciSparc jumps 150.8% as subsidiary wins conditional exchange approval for CliniQuantum deal - Quiver Quantitative
Why Is SciSparc Stock Skyrocketing On Thursday? - Benzinga
SciSparc Ltd. (SPRC) Stock Explodes 202% Following NeuroThera's TSX Exchange Milestone - Blockonomi
SciSparc (SPRC) Stock Rockets 202% as NeuroThera Gets TSX Green Light - MoneyCheck
NeuroThera receives conditional approval for CliniQuantum deal - Investing.com UK
SciSparc stock surges 200% on NeuroThera acquisition progress By Investing.com - Investing.com India
SciSparc’s NeuroThera Labs Gets Conditional Approval to Acquire CliniQuantum - geneonline.com
Trending Stocks Today | SciSparc Shoots up 219.58% - Moomoo
SPRC Stock Explodes As Bullish Upgrades Hit Tape - StocksToTrade
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum - markets.businessinsider.com
NeuroThera receives conditional approval for CliniQuantum deal By Investing.com - Investing.com Nigeria
SPRC Stock Draws Bullish Upgrades As Traders Circle - timothysykes.com
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition ... - Caledonian Record
SciSparc-backed NeuroThera plans approx. $9.46M quantum clinical trial tech buy - Stock Titan
Neurothera Labs Inc. Provides Update On Proposed Acquisition Of Majority Stake In Cliniquantum Ltd. - TradingView
SciSparc Ltd. (SPRC) Gains 2.07% in Light Trading – Key Support Holds Above $4.00Price Target - The Legal Advocate
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - MSN
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):